Linde has today said it is pleased with the decision by the US Supreme Court declining to review the 2019 appeals court decision that affirmed Praxair Distribution, Inc.’s (PDI) right to sell a generic form of inhaled nitric oxide.
The decision ends the long-running US patent litigation with Mallinckrodt plc, and affirms the ability of PDI, a wholly owned subsidiary of Linde, to continue supplying inhaled nitric oxide.
The drug product is widely use as approved in the in US and other countries to improve oxygenation of certain groups of patients.
“Nitric oxide is truly a unique and beneficial drug,” said Ben Glazer, President of US Packaged & Specialty Gases.
... to continue reading you must be subscribed
